Abstract
The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Current Pharmaceutical Design
Title:Why do Psychotic Patients use Cannabis? Case Series
Volume: 18 Issue: 32
Author(s): Anna Kolliakou, Khalida Ismail and Zerrin Atakan
Affiliation:
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Abstract: The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Export Options
About this article
Cite this article as:
Kolliakou Anna, Ismail Khalida and Atakan Zerrin, Why do Psychotic Patients use Cannabis? Case Series, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884807
DOI https://dx.doi.org/10.2174/138161212802884807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Current Cardiology Reviews Nano-Lipid-Carriers for the Treatment of Vitiligo: A Recent Update, Pathophysiology and Mechanism of Drug Delivery
Current Molecular Pharmacology Inflammatory Mediators in Smoke Inhalation Injury
Inflammation & Allergy - Drug Targets (Discontinued) Palliative Combined Percutaneous Balloon Aortic Valvuloplasty and Unprotected Left Main Stenting in End Stage Renal Disease
Current Cardiology Reviews Utilizing Delta Opioid Receptors and Peptides for Cytoprotection: Implications in Stroke and Other Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Prophylactic Use of Antiepileptic Drugs in Patients Scheduled for Neurosurgery
Current Pharmaceutical Design Rheological Characteristics of Novel Meloxicam-Loaded Complex Organogels Based on Fumed Silica and Poloxamer
Current Drug Delivery Pharmacological Management of Psychosis in Parkinson Disease: A Review
Current Drug Therapy Azoles: Mode of Antifungal Action and Resistance Development. Effect of Miconazole on Endogenous Reactive Oxygen Species Production in Candida albicans
Anti-Infective Agents in Medicinal Chemistry Differences in Sexual Risk Behaviors Between Lower and Higher Frequency Alcohol-Using African-American Adolescent Females
Current HIV Research Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry Lower Financial Status and Adherence to Medication Determines 10-Year (2004-2014) All-Cause Mortality and Risk for Acute Coronary Syndrome Incidence Among Cardiac Patients: the GREECS Study
Current Vascular Pharmacology The Chemokine CXCL10 as a Therapeutic Target in Animal Models of Neuroinflammatory Disease
Letters in Drug Design & Discovery Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design Stem Cell Niche in Tissue Homeostasis, Aging and Cancer
Current Medicinal Chemistry Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets
Current Neuropharmacology Inpatient Care of the HIV Infected Patient in the Highly Active Antiretroviral Therapy (HAART) Era
Current HIV Research Editorial: Design and Algorithms in Biomedical Engineering
Neuroscience and Biomedical Engineering (Discontinued) Calcium Signaling, PKC Gamma, IP3R1 and CAR8 Link Spinocerebellar Ataxias and Purkinje Cell Dendritic Development
Current Neuropharmacology